Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials
Michał Marczyk, Lajos Pusztai(Yale University), Angela DeMichele(University of Pennsylvania), Denise M. Wolf, M.C. Liu(Mayo Clinic in Arizona), Sonal Shad(University of California, San Francisco), Adam L. Asare(Quantum Leap Healthcare Collaborative), Judy C. Boughey(Mayo Clinic in Arizona), Douglas Yee(University of Minnesota Medical Center), Husain Sattar(University of Chicago), Y.-Y. Chen(University of California, San Francisco), Smita Asare(Quantum Leap Healthcare Collaborative), Anna Mrukwa(Silesian University of Technology), Meredith Buxton(Center for Effective Global Action), Barbara A. Parker(University of California San Diego), Amrita Basu(University of Calcutta), Kathy S. Albain(Loyola University Chicago), Christina Yau(Hospital Authority), Amy S. Clark(Abramson Center for Jewish Life), Sara J. Venters(University of California, San Francisco), Jane Perlmutter(Gemini Computers (United States)), Laura J. Esserman(University of California, San Francisco), Ronald Balassanian, Donald A. Berry(Berry & Associates (United States)), Jay Zeck(Georgetown University), Hope S. Rugo(City of Hope), Anthony Elias(University of Colorado Cancer Center), Gregor Krings(Cleveland Clinic), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Laura Van't Veer(University of California, San Francisco), Rita Nanda(University of Chicago)
Cited by 22
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k